googlescholar-adv.jpg
Medicine

Molecular Medicine at IgMin Research | Medicine Group

Our mission is to foster interdisciplinary dialogue and accelerate the advancement of knowledge across a wide spectrum of scientific domains.

About

Molecular medicine is a cutting-edge discipline that merges insights from molecular biology, genetics, and medicine to understand the underlying mechanisms of diseases at the molecular level. This field seeks to unravel the intricate molecular pathways and cellular processes that contribute to health and disease. By dissecting the molecular basis of disorders, researchers can develop targeted therapies, precision medicine approaches, and innovative diagnostic tools.

The study of molecular medicine involves investigating genes, proteins, signaling pathways, and other molecular components that drive biological functions. This knowledge is integral for identifying biomarkers, understanding disease progression, and devising strategies to intervene and restore cellular balance. Molecular medicine has revolutionized the way we approach diagnosis, treatment, and prevention of a wide range of medical conditions.

  • Genetic Disorders and Therapies
  • Molecular Diagnostics
  • Molecular Imaging
  • Precision Medicine
  • Biomarker Discovery
  • Molecular Pathology
  • Pharmacogenomics
  • Personalized Therapeutics
  • Molecular Oncology
  • Molecular Immunology
  • Molecular Neurobiology
  • Cellular Signaling
  • Molecular Targets for Drug Development
  • Molecular Epidemiology
  • Molecular Genetics
  • Proteomics
  • Transcriptomics
  • Metabolomics
  • Molecular Mechanisms of Aging
  • Molecular Cardiology
  • Molecular Hematology
  • Molecular Endocrinology
  • Molecular Infectious Diseases
  • Molecular Theranostics
  • Molecular Health Interventions

Medicine Group (1)

Research Article Article ID: igmin187
Cite

Open Access Policy refers to a set of principles and guidelines aimed at providing unrestricted access to scholarly research and literature. It promotes the free availability and unrestricted use of research outputs, enabling researchers, students, and the general public to access, read, download, and distribute scholarly articles without financial or legal barriers. In this response, I will provide you with an overview of the history and latest resolutions related to Open Access Policy.

Examining the Causal Connection between Lipid-lowering Medications and Malignant Meningiomas through Drug-target Mendelian Randomization Analysis
by Liantai Song, Xiaoyan Guo, Wenhui Zhang, Mengjie Li, Xinyi Wu, Ziqian Kou, Yuxin Wang, Zigeng Ren and Qian Xu

Objectives: This study aims to investigate the causal link between the use of statins, a type of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and the risk of developing malignant meningiomas, which are aggressive and recurrent tumors of the central nervous system with limited treatment options.Methods: Using Mendelian Randomization (MR) analysis, the study explored the relationship between genetic variants related to the expression of lipid-lowering drug targets (HMGCR, PCSK9, NPC1L1, and APOB) and malignant meningiomas.... The analysis utilized data from Genome-Wide Association Studies (GWAS) and expression quantitative trait loci (eQTL) databases, with a focus on the genetic homogeneity of the Finnish population. Instrumental variables for the MR analysis were derived from significant eQTLs for the mentioned drug targets.Results: The MR analysis found a significant association between genetic variants linked to HMGCR inhibitor (statin) exposure and a reduced risk of malignant meningiomas. Specifically, an increased expression of the HMGCR gene in the blood was associated with lower susceptibility to malignant meningiomas (Odds Ratio [OR] = 2.57, 95% Confidence Interval [CI] = 1.05 - 6.31; p = 0.039). No significant associations were observed for other lipid-lowering drug targets.Conclusion: Preliminary evidence suggests that statin use may lower the risk of developing malignant meningiomas, indicating a potential therapeutic benefit for managing this type of cancer. However, further research, including clinical trials, is necessary to confirm these findings and understand the mechanisms behind the protective effect of statins against malignant meningiomas.

Pharmacology Molecular Medicine